Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern

Vandana Singh

June 23, 2025

Benzinga

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.

Latest Ratings for NVO

Date	Firm	Action	From	To
Jan 2022	Liberum	Downgrades	Hold	Sell
Dec 2021	JP Morgan	Downgrades	Overweight	Neutral
Jan 2021	Deutsche Bank	Initiates Coverage On		Buy

View More Analyst Ratings for NVO

View the Latest Analyst Ratings

Market Impact

Coinbase Stock Is S&P 500's Best Performer For June: How It Got There

June 28, 2025

Benzinga

Market Impact

Melinda French Gates Reveals The No. 1 Skill Women Need To Reach The C-Suite: 'You Learn To Fail And That Failing Is...'

June 28, 2025

Benzinga

Market Impact

Runway Ready: Can Aviation Safety Tech Be The Next Frontier For Aerospace ETFs?

June 28, 2025

Benzinga

Market Impact

Coinbase Stock Is S&P 500's Best Performer For June: How It Got There

June 28, 2025

Benzinga

Market Impact

Melinda French Gates Reveals The No. 1 Skill Women Need To Reach The C-Suite: 'You Learn To Fail And That Failing Is...'

June 28, 2025

Benzinga

Market Impact

Runway Ready: Can Aviation Safety Tech Be The Next Frontier For Aerospace ETFs?

June 28, 2025

Benzinga

Business & Finance

America cannot afford to break global investor trust

March 31, 2025

Financial Times

Markets

‘Bulldog’ Ex-Goldman Banker Answers Carney’s Call to Fix Canada Resources Sector

May 13, 2025

Bloomberg

Markets

S&P Heads For Worst Week Since COVID | Bloomberg Markets

April 4, 2025

Bloomberg

Enjoy premium content in your inbox.

You're in! Check your email to learn more.

Oops! Something went wrong while submitting the form.

Novo Nordisk's Weight Loss Injection CagriSema Data Sparks Investor Concern

Latest Ratings for NVO

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

News

Tools

More

Follow